<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127921">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02117375</url>
  </required_header>
  <id_info>
    <org_study_id>2013-A00333-42</org_study_id>
    <secondary_id>PHRC/12-07</secondary_id>
    <nct_id>NCT02117375</nct_id>
  </id_info>
  <brief_title>EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients</brief_title>
  <acronym>EMISEP</acronym>
  <official_title>EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the prognostic value of early focal lesions and
      early diffuse lesions on ambulatory disability progression within 5 years after clinical
      onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicentric study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Progressive neurological disability</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement by Expended Disability Status Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive ambulatory disability</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement by the 25-foot timed-Walked test and 6 minutes walking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive disability in the upper limbs</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement by the nine-hole peg test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive urinary disability</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement by the questionnaire Qualiveen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive difficulty walking</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement by the Multiple Sclerosis Walking Scale 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Patients with multiple sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 patients / clinical Follow-up at M0, M6, M12, M18, M24, M30, M36, M42, M48, M54 and M60 / spinal cord MRI follow-up at M0, M12, M24, M36 and M60 / brain MRI follow-up at M0, M12, M24, M36 and M60</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 healthy volunteers (stability of spinal cord imaging) / spinal cord MRI follow-up at M0 and M24</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>spinal cord MRI follow-up</intervention_name>
    <description>Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio</description>
    <arm_group_label>Patients with multiple sclerosis</arm_group_label>
    <arm_group_label>Healthy volunteers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clinical follow-up</intervention_name>
    <description>Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty</description>
    <arm_group_label>Patients with multiple sclerosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>brain MRI follow-up</intervention_name>
    <arm_group_label>Patients with multiple sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with multiple sclerosis:

        Inclusion Criteria:

          -  Relapsing Remitting Multiple Sclerosis patients (Mac Donald 2010 criteria)

          -  First clinical event &lt; 1 year

          -  Brain MRI &gt; 9 lesions or/and spinal cord attack with focal lesion on spinal cord MRI

          -  Score Expended Disability Status Scale &lt; 3

          -  Age between 18 and 40 years

        Exclusion Criteria:

          -  Multiple Sclerosis progressive

          -  Patients treated with immunosuppressive therapy

          -  Pregnancy

        Healthy volunteers:

        Inclusion Criteria:

        -Age between 18 and 40 years

        Exclusion Criteria:

        -Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles GE Edan</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno BB Brochet</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thibault TM Moreau</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Dijon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sandra SV Vukusic</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices civils Lyon</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean JP Pelletier</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc MD Debouverie</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno BS Stankoff</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pitié Salpêtrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman AT Tourbah</last_name>
    <role>Study Director</role>
    <affiliation>CHU Reims</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jérôme JD De Seze</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Strasbourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David DB Brassat</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilles GE Edan</last_name>
    <phone>33-2-9928-4122</phone>
    <email>gilles.edan@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gilles GE Edan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>spinal cord</keyword>
  <keyword>MRI</keyword>
  <keyword>longitudinal study</keyword>
  <keyword>disability</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
